Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer ; volume:20 ; number:1 ; day:16 ; month:4 ; year:2020 ; pages:1-11 ; date:12.2020
Cancer cell international ; 20, Heft 1 (16.4.2020), 1-11, 12.2020
- Creator
-
Yan, Xiao-Yu
Qu, Xian-Zhi
Xu, Long
Yu, Si-Hang
Tian, Rui
Zhong, Xin-Ru
Sun, Lian-Kun
Su, Jing
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-020-01196-w
- URN
-
urn:nbn:de:101:1-2020062822594700145494
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yan, Xiao-Yu
- Qu, Xian-Zhi
- Xu, Long
- Yu, Si-Hang
- Tian, Rui
- Zhong, Xin-Ru
- Sun, Lian-Kun
- Su, Jing
- SpringerLink (Online service)
Other Objects (12)
Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer
Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
New approaches for cisplatin-resistant bladder cancer
Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells
Insight into the current practice of ototoxicity monitoring during cisplatin therapy
Promising Novel Therapeutic Strategies for Cisplatin Resistant Bladder Cancer
Increased HRD score in cisplatin resistant penile cancer cells
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells
Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer
Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
New approaches for cisplatin-resistant bladder cancer
Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells
Insight into the current practice of ototoxicity monitoring during cisplatin therapy
Promising Novel Therapeutic Strategies for Cisplatin Resistant Bladder Cancer
Increased HRD score in cisplatin resistant penile cancer cells
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells
Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer
Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
New approaches for cisplatin-resistant bladder cancer
Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
Cytotoxicity of some synthetic bis(arylidene) derivatives of cyclic ketones towards cisplatin-resistant human ovarian carcinoma cells
Insight into the current practice of ototoxicity monitoring during cisplatin therapy
Promising Novel Therapeutic Strategies for Cisplatin Resistant Bladder Cancer
Increased HRD score in cisplatin resistant penile cancer cells